ESUS Fails But Hurt Minimal for Bayer/Janssen's Xarelto
Bayer and Janssen's bid for NOAC dominance through diversification has hit a buffer with the failure of a Phase III trial in stroke, but the indication is small and not expected to hit sales that much.
You may also be interested in...
J&J will be talking to FDA regarding expanded approval for peripheral arterial disease and coronary artery disease following early stop of COMPASS outcomes study; strong data will be needed if asymptomatic patients are targeted.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.